ABSTRACT
Objective:To investigate the clinical characteristics of acute myeloid leukemia with BCR-ABL p210 fusion gene-positive.Methods:The clinical characteristics of a patient diagnosed in the Second Hospital of Jiaxing were analyzed and the related literature was reviewed.Results:BCR-ABL p210 fusion gene and Philadelphia chromosome (Ph) were detected by reverse transcription-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH). Imatinib associated with multi-drug intravenous chemotherapy resulted in poor efficacy.Conclusions:Patient with Ph +/BCR-ABL + acute myeloid leukemia is rare with a very poor prognosis. There is no unified standard treatment and the efficacy of tyrosine kinase inhibitors is unclear. Intravenous chemotherapy combined with hematopoietic stem cell transplantation is expected to change the prognosis.
ABSTRACT
Objective To study and explore the clinical effect of imatinib mesylate in the treatment of chronic myeloid leukemia. Methods From January 2013 to January 2017,60 patients with chronic myeloid leukemia in the Second Hospital of Jiaxing were included in the study. The patients were randomly divided into control group and observation group,with 30 cases in each group. The control group was given routine chemotherapy, the observation group was given routine chemotherapy combined wth imatinib mesylate orally. After 6 months of treatment,the clinical curative effect, the incidence of adverse reactions, immune function, quality of life score of the two groups were compared. Results The response rate of the observation group was 76. 67％ (23/30),which was higher than 50. 00％(15/30) of the control group (χ2 =4. 593,P <0. 05). The incidence rate of adverse reactions in the observation group was 13. 33％(4/30),which was significantly lower than 36. 67％(11/30) in the control group (χ2 =4. 356,P<0. 05). Before treatment,the immune function indicators between the two groups had no statistically significant differences (t=0. 168,0. 287,0. 156,all P>0. 05). After treatment,the indicators of immune function in the observation group were higher than those in the control group(t =4. 482,3. 731,3. 361,all P <0. 05). After treatment,the quality of life scores in the observation group were higher than those in the control group( t=8. 898, 5. 945,9. 309,5. 679,all P<0. 05). Conclusion Imatinib mesylate in the treatment of patients with chronic myelog-enous leukemia can effectively improve the efficacy and safety of chemotherapy,reduce the effect of chemotherapy on the immune function of patients,improve their quality of life.
ABSTRACT
Objective To investigate the significance of serum interleukin-1β,interleukin-2,interleukin-6,TNF-α,erythrocyte sedimentation rate(ESR),c-reactive protein(CRP),IgA,IgG and IgM in patients with ankylosing spondylitis(AS),and to analyze their relationship with the Bath ankylosing spondylitis disease activity index (BASDAI). Methods Participants of this study included 45 AS patients(patient group)and 30 healthy subjects (control group).The patient group was further divided into an active subgroup and an inactive subgroup based on the disease activity assessed by using BASDAI.Then serum levels of IL-1β,IL-2,IL-6,TNF-α,ESR,CRP,IgA,IgC and IgM were tested in all the subjects,and the values were compared between different groups.In addition,the relationship between various parameters and those with BASDAI were also evaluated. Results The serum levels of ESR,CRP,IgA,lgM,IgG,IL-1β,IL-2,IL-6 and TNF-α in patients with AS were significantly higher than those in the healthy controls(P<0.05).The serum level of CRP,IL-2 and IL-6 were significantly different between the active and inactive subgroups(P<0.05).There was a positive correlation between CRP and IL-6,IL-6 and IL-2,as well as IgA and IgG levels.The IL-2,IL-6 and CRP levels were positive correlated with BASDAI.Conclusion It was suggested that the serum levels of IL-2,IL-6 and CRP can be used to assess the disease activity in patients with AS.